Q1 Earnings Forecast for Immatics Issued By Leerink Partnrs

Immatics (NASDAQ:IMTX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Immatics in a research note issued to investors on Thursday, March 27th. Leerink Partnrs analyst J. Chang expects that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share. Leerink Partnrs also issued estimates for Immatics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS and Q4 2025 earnings at ($0.41) EPS.

Immatics (NASDAQ:IMTX) last posted its earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.51. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The firm had revenue of $15.67 million for the quarter, compared to analyst estimates of $16.16 million.

Immatics Stock Performance

IMTX stock opened at $4.51 on Monday. The company’s 50 day moving average price is $4.94 and its 200 day moving average price is $7.37. The firm has a market capitalization of $538.30 million, a price-to-earnings ratio of -6.83 and a beta of 0.83. Immatics has a fifty-two week low of $4.06 and a fifty-two week high of $13.77.

Institutional Trading of Immatics

Several institutional investors have recently modified their holdings of IMTX. Wellington Management Group LLP lifted its position in Immatics by 7.6% during the 4th quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company’s stock worth $74,071,000 after acquiring an additional 736,709 shares during the period. Frazier Life Sciences Management L.P. boosted its stake in shares of Immatics by 58.6% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 2,147,911 shares of the company’s stock valued at $15,272,000 after buying an additional 793,200 shares in the last quarter. Zimmer Partners LP grew its holdings in Immatics by 44.6% during the fourth quarter. Zimmer Partners LP now owns 405,000 shares of the company’s stock worth $2,880,000 after acquiring an additional 125,000 shares during the period. Vestal Point Capital LP lifted its holdings in Immatics by 67.3% in the fourth quarter. Vestal Point Capital LP now owns 6,275,000 shares of the company’s stock valued at $44,615,000 after acquiring an additional 2,525,000 shares during the period. Finally, Suvretta Capital Management LLC purchased a new stake in shares of Immatics during the 4th quarter worth $36,014,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.